Thus, it is hypothesised that mTOR activation upregulates SREBP activity, which in turn promotes FADS2 overexpression, contributing to ferroptosis resistance in bladder cancer cells and facilitating cancer progression. The gene discussed is FADS2; the disease is urinary bladder carcinoma.